Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Along with these positives, this Zacks #2 Rank (Buy) companys 1.6% dividend yield and a continuous share buyback program make its stock a good pick for investors looking for both growth and income.
Fourth Quarter Results
On May 24, Patterson reported fourth quarter fiscal 2012 adjusted earnings per share of 58 cents, beating the Zacks Consensus Estimate by a penny and the year-ago earnings of 53 cents per share. For fiscal 2012, adjusted earnings of $1.92 per share beat the Zacks Consensus Estimate by a penny and exceeded the prior years EPS of $1.89.
Revenues for the fourth quarter rose 6% year over year to $936.3 million, beating the Zacks Consensus Estimate of $914 million. The upside was driven by robust performance across the three segments Dental Supply (grew 4%), Rehabilitation Supply (3%) and Veterinary Supply (13%). Sales from the Webster Veterinary unit were boosted by the August 2011 acquisition of American Veterinary Supply Corporation that accounted for approximately 2% of the units sales growth.
For the fiscal year, revenues grew 3.5% to $3,535.7 million, slightly above the Zacks Consensus Estimate of $3,510 million. An additional sales week in the first quarter of fiscal 2011 had an adverse impact on year-over-year comparison by approximately 2 percentage points.
Gross margin dropped 90 basis points year over year to 33.5% in the fourth quarter. In addition, a 5.5% rise in operating expenses to $210.9 million led to an 80 bps contraction in operating margin to 11%.
For fiscal 2013 the company forecasts EPS between $2.10 and $2.16, representing year-over-year growth of 9.4% to 12.5%. While the dental consumables and equipment markets are expected to grow by 2% to 3% and 5 to 7%, respectively, the companion pet veterinary market is slated for 3 to 4% growth during fiscal 2013. However, the global rehabilitation market is expected to remain flat.
Estimates Inch Up
Patterson is expected to report first quarter fiscal 2013 results on August 23, 2012. The Zacks Consensus Estimate for fiscal 2013 remained unchanged at $2.14, slightly below the companys guidance. However, the Zacks Consensus Estimate for fiscal 2014 has increased by 2.0% to $2.36 over the last 30 days, representing a year-over-year jump of 10.6%.
Enhancing Shareholder Value
In March 2012, Patterson hiked its quarterly dividend by 16.7% to 14 cents per share, representing a decent yield of 1.6%. In contrast, the average dividend yield of the industry is only 0.4%. Since the company initiated its dividend in March 2010 with 10 cents per share, dividends have grown at a compound annual growth rate of 18.0%. The companys dividend payout ratio has also gone up from 22.0% in fiscal 2010 to approximately 28.6% in the current fiscal year.
The company returned over $400 million to its shareholders in fiscal 2012 including share buybacks and quarterly dividends.
Attractive Valuation
Pattersons valuation looks compelling compared to its peers by most metrics. Based on 2013 earnings estimates, the company is trading at a price-to-earnings (P/E) of 16.40x, a nominal discount to the peer group average of 16.52x. The price-to-book of 2.83x is at an 8.1% discount to the peer group average of 3.08x. Valuation looks attractive with respect to the price-to-sales (P/Sales) ratio as well. The P/Sales ratio of the company stood at 1.09, a 34.7% discount to the peer group average of 1.67.
Chart Reflects Strength
The stock has been consistently trading above its 200-day moving average since January 19, 2012. Barring occasional pullbacks, the stock has been above its 50-day moving average since the beginning of the year. Patterson, which competes with players such as Henry Schein (HSIC) and MWI Veterinary Supply (MWIV), has also outperformed the S&P 500 since April 30, 2012. The one-year return for the stock is roughly 10.3% compared to a 3.5% return from the S&P 500 index.
Headquartered in St. Paul, Minnesota, Patterson Companies Inc. ( PDCO - Analyst Report ) is a leading distributor of dental, companion-pet veterinarian, and rehabilitation supply in the US and Canada. Patterson Dental is the companys largest business segment and one of the two largest distributors of dental products in North America. Patterson is also the only national dealer for A-dec equipment that is the largest manufacturer of dental equipment in the U.S. It has a market capitalization of $3.71 billion.
Read the full reports :
Analyst Report on PDCO